A randomised controlled trial of blood pressure self-monitoring in the management of hypertensive pregnancy. OPTIMUM-BP:A feasibility trial by Pealing, Louise M. et al.
                          Pealing, L. M., Tucker, K. L., Mackillop, L. H., Crawford, C., Wilson, H.,
Nickless, A., ... McManus, R. J. (2019). A randomised controlled trial of
blood pressure self-monitoring in the management of hypertensive
pregnancy. OPTIMUM-BP: A feasibility trial. Pregnancy Hypertension, 18,
141-149. https://doi.org/10.1016/j.preghy.2019.09.018
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.preghy.2019.09.018
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.sciencedirect.com/science/article/pii/S2210778919304441#! . Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Contents lists available at ScienceDirect
Pregnancy Hypertension
journal homepage: www.elsevier.com/locate/preghy
A randomised controlled trial of blood pressure self-monitoring in the
management of hypertensive pregnancy. OPTIMUM-BP: A feasibility trial
Louise M. Pealinga,⁎, Katherine L. Tuckera, Lucy H. Mackillopb, Carole Crawforda,
Hannah Wilsonc, Alecia Nicklessa,d, Eleanor Templea, Lucy C. Chappellc,1, Richard J. McManusa,1,
on behalf of the OPTIMUM-BP Investigators2
aNuﬃeld Department of Primary Care Health Sciences, University of Oxford, Radcliﬀe Primary Care, Radcliﬀe Observatory Quarter, Woodstock Road, Oxford OX2 6GG,
UK
bWomen’s Centre, Oxford University Hospitals NHS Foundation Trust, Level 6, John Radcliﬀe Hospital, Headley Way, Oxford OX3 9DU, UK
c Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, 10th Floor North Wing, St Thomas’ Hospital, Westminster Bridge
Road, London SE1 7EH, UK
dAtmospheric Chemistry Research Group, School of Chemistry, University of Bristol, Cantock’s Close BS8 1TS, UK
A R T I C L E I N F O
Keywords:
Blood pressure
Hypertension
Pregnancy
Self-monitoring
Maternal outcome
Perinatal outcome
A B S T R A C T
Objective: To assess the feasibility of a blood pressure self-monitoring intervention for managing pregnancy
hypertension.
Study design: OPTIMUM-BP was an unmasked randomised controlled trial comparing a self-monitoring of blood
pressure (SMBP) intervention versus usual care for the management of pregnancy hypertension. Women with
chronic (CH) or gestational hypertension (GH) from 4 UK centres were randomised (2:1) intervention to control.
Self-monitoring involved daily home blood pressure (BP) measurements, with recording via study diary or
telemonitoring. Clinicians were invited to use the home readings in clinical and antihypertensive titration de-
cisions.
Main outcomes: The primary outcomes were recruitment, retention, adherence and persistence with the inter-
vention.
Results: Women from four UK centres were randomised: 158/222 (71%) of those approached agreed, com-
prising: 86 women with chronic hypertension (55 SMBP, 31 control) and 72 with gestational hypertension (49
SMBP, 23 control) of whom outcome data were available from 154 (97%) and were included in the analysis. The
median (IQR) number of days with home BP readings per week were 5.5 (3.1–6.5) for those with chronic
hypertension and 6.1 (4.5–6.7) with gestational hypertension. Participants persisted with the intervention for
80% or more of their time from enrolment until delivery in 86% (43/50) and 76% (38/49) of those with chronic
and gestational hypertension respectively. Recorded clinic and study BPs were similar for both groups.
Conclusions: This is the ﬁrst randomised investigation of BP self-monitoring for the management of pregnancy
hypertension and indicates that a large RCT would be feasible.
1. Introduction
Hypertensive disorders of pregnancy are common and associated
with substantial maternal and perinatal morbidity and mortality [1,2].
Much of the research and clinical focus has previously been on the
timely detection and eﬀective management of preeclampsia and
eclampsia. There has been conﬂicting evidence and limited guidance
regarding managing non-proteinuric hypertension in pregnancy, with a
recognition that severe hypertension is a risk factor for maternal stroke
[3–5] but it is also necessary to seek to avoid possible iatrogenic risks of
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controlling blood pressure (BP), such as reduced fetal growth. The re-
cent Control of Hypertension in Pregnancy Study (CHIPS) showed that
tight (diastolic target of 85mmHg) versus less-tight control (diastolic
target of 105mmHg) of BP in hypertensive pregnancies was associated
with a reduced incidence of maternal severe hypertension without a
consequent increase in adverse perinatal outcomes, and a secondary
analysis showed that severe hypertension was associated with multiple
adverse maternal and perinatal outcomes independent of the develop-
ment of preeclampsia [6,7]. However the optimal approach to ob-
taining BP control in pregnancy and therefore avoiding severe hy-
pertension is uncertain. Currently, pregnant women with hypertensive
disorders usually have more frequent clinic surveillance to monitor for
any deterioration in BP, assessing for emerging preeclampsia and fetal
complications associated with pregnancy hypertension [8]. Not only
does this place a considerable burden on both the health service and
importantly the woman herself, but deterioration may occur between
clinic visits [9,10].
In the general adult population with chronic hypertension, evidence
shows that BP self-management that includes self-monitoring and ti-
tration of antihypertensives leads to signiﬁcantly improved BP control
and higher patient satisfaction [11–14]. Previous small, mostly non-
randomised studies of BP self-monitoring in the pregnant population
[15–17] suggest a similar approach may be feasible and acceptable.
OPTIMUM-BP used a BP self-monitoring intervention developed
from other self-monitoring BP trials [11,18] for use by pregnant women
with hypertension. This trial was designed to study the feasibility and
acceptability of a BP self-monitoring intervention in the management of
hypertension in pregnancy. It aimed to inform the further development
Fig. 1. OPTIMUM-BP CONSORT (Consolidated Standards of Reporting Trial) ﬂowchart. *No data available after baseline.
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of the intervention and processes for use in a future large randomised
controlled trial (RCT), to investigate the eﬀectiveness of this interven-
tion for blood pressure control during pregnancy.
2. Methods
OPTIMUM-BP was an unmasked randomised controlled clinical trial
including pregnant women with chronic or gestational hypertension.
The trial compared hypertensive management utilising clinic BP alone
vs management supplemented by self-monitoring of BP. The study
protocol and materials were approved by the UK Research Ethics
Committee (15/EM/0490) and research and development approvals
gained. All study participants provided written, informed consent. Trial
registration: DOI 10.1186/ISRCTN16018898.
2.1. Participants
Pregnant women with hypertension were enrolled by study in-
vestigators from four National Health Service (NHS) maternity units in
England. Eligibility criteria included women aged ≥18 years with a
singleton pregnancy and with chronic or gestational hypertension,
without preeclampsia. Women with chronic hypertension (treated or
not) could have a prenatal diagnosis of hypertension or sustained BP
readings ≥140mmHg systolic and/or ≥90mmHg diastolic before
20 weeks’ gestation, and were recruited any time between booking and
23+6 weeks’ gestation. Women with gestational hypertension, deﬁned
as sustained BP readings ≥140mmHg systolic and/or ≥90mmHg
diastolic after 20 weeks’ gestation and without proteinuria, were re-
cruited between 20 and 37+6 weeks’ gestation. Women were excluded
if they were unwilling to self- monitor, had insuﬃcient understanding
of the study or had preeclampsia (as deﬁned by the International
Society for the Study of Hypertension in Pregnancy 2014 statement)
Table 1
Demographic and clinical characteristics at enrolment of 158 pregnant women with hypertension included in the OPTIMUM-BP feasibility trial from December 2015
until December 2017.
Chronic Hypertension Gestational Hypertension
Characteristic Randomised to SMBP
(n= 55)
Randomised to usual care
(n= 31)
Randomised to SMBP
(n= 49)
Randomised to usual care
(n= 23)
Age in years* 35.9 (5.6) 35.5 (4.2) 33.4 (5.9) 34.2 (5.1)
Gestation at recruitment in weeks† 16.6
(12.9 to 20.1)
14.9
(13.0 to 20.0)
35.0
(32.4 to 36.1)
34.7
(32.1 to 36.4)
Body mass index* (kg/m2) 31.0 (7.0) 31.9 (7.0) 29.5 (7.1) 27.6 (6.4)
Ethnicity
White 27 (49%) 21 (68%) 37 (76%) 18 (78%)
Black 21 (38%) 8 (26%) 11 (22%) 4 (18%)
Asian 6 (11%) 2 (6%) 1 (2%) 1 (4%)
Other 1 (2%) 0 (0%) 0 (0%) 0 (0%)
Deprivation quintile‡
1st – least deprived 18 (33%) 7 (23%) 13 (27%) 4 (17%)
2nd 13 (24%) 7 (23%) 10 (20%) 6 (26%)
3rd 7 (13%) 9 (29%) 7 (15%) 5 (22%)
4th 9 (16%) 6 (19%) 9 (18%) 3 (13%)
5th – most deprived 6 (10%) 2 (6%) 9 (18%) 3 (13%)
Unknown 2 (4%) 0 (0%) 1 (2%) 2 (9%)
Highest educational qualiﬁcation
Professional/Higher qualiﬁcations 36 (65%) 16 (52%) 37 (76%) 20 (87%)
School qualiﬁcations 15 (27%) 14 (45%) 9 (18%) 3 (13%)
No formal qualiﬁcations 3 (6%) 1 (3%) 1 (2%) 0 (0%)
Unknown 1 (2%) 0 (0%) 2 (4%) 0 (0%)
Smoking history
Never smoked 39 (71%) 26 (84%) 40 (82%) 17 (74%)
Quit before pregnancy 9 (16%) 4 (13%) 8 (16%) 4 (18%)
Smoking during pregnancy 5 (9%) 0 (0%) 0 (0%) 1 (4%)
Not known 2 (4%) 1 (3%) 1 (2%) 1 (4%)
Other self-reported medical history4
Diabetes type 1 0 (0%) 1 (3%) 0 (0%) 1 (4%)
Diabetes type 2 2 (4%) 3 (10%) 1 (2%) 0 (0%)
Chronic kidney disease 1 (2%) 1 (3%) 0 (0%) 0 (0%)
Asthma 7 (13%) 4 (13%) 5 (10%) 1 (4%)
Parity
0 17 (31%) 9 (29%) 20 (41%) 14 (61%)
≥1 38 (69%) 22 (71%) 29 (59%) 9 (39%)
Diagnosis of preeclampsia or gestational hypertension in previous
pregnancy
20 (53%) 16 (73%) 15 (52%) 5 (56%)
Proportion prescribed** antihypertensive medication at enrolment 40 (73%) 21 (68%) 30 (61%) 15 (65%)
Blood pressure at enrolment in mmHg*
Systolic 136.6 (13.8) 139.5 (13.1) 139.5 (14.0) 137.3 (1.3)
Diastolic 85.9 (10.1) 87.4 (11.5) 86.9 (9.9) 87.9 (8.0)
Previous SMBP in this pregnancy at least once 25 (45%) 16 (52%) 14 (29%) 5 (21%)
Abbreviations: CH: Chronic hypertension; GH: Gestational hypertension; SMBP: Self-monitoring blood pressure; BP: Blood pressure; SD: Standard deviation; N:
Number; IQR: Interquartile range.
* Mean and SD.
† Median and interquartile range.
‡ Deprivation measured as Index of Multiple Deprivation score using Oﬃce of National Statistics for England data [24].
** Participants’ self-reported medication history.
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[19] at time of enrolment.
2.2. Procedures
Eligible and consented women completed a baseline assessment
including questionnaires on quality of life scores (EQ-5D-5L) [20],
measurement of anxiety (STAI-6) [21] and medication beliefs (BMQ)
[22] and medication adherence (MARS) [23]. Members of the research
team obtained study BP measurements and data on demographics,
medical and obstetric history, current and past antihypertensive
therapy and socioeconomic status (Index of Multiple Deprivation) [24].
Women were randomised, stratiﬁed for recruiting centre and type of
hypertension, in permuted blocks of random size (2 or 4) in a 2:1 ratio
to BP self-monitoring or usual care. Women randomised to the inter-
vention also received all usual care, and no antenatal visits were re-
moved from their schedule. The randomisation sequence was computer-
generated, and secure web-based software was used to ensure alloca-
tion concealment, although due to the nature of the intervention, nei-
ther participants nor investigators or clinicians were masked. Outcome
measurement was not masked. Study visit BP readings were taken with
an automated, validated monitor to minimise bias.
Women allocated to usual care had their BP monitored by their local
clinical team, and these BPs measured by healthcare professionals were
used to inform care and decisions around antihypertensive medication.
Women randomised to the intervention were additionally asked to
measure their BP daily, at approximately the same time each day, using
an automated BP monitor (Microlife WatchBP Home) validated in
pregnancy and preeclampsia, after measuring and recording upper-arm
diameter to select appropriate cuﬀ size [25]. Participants were asked to
take two readings, at least one minute apart, and to record the second in
their study diary, or submit the reading using their mobile phone, via
text or the study App (the App was available for the women with ge-
stational hypertension only, during the latter phase of the study). The
digitally reported readings were automatically transmitted to a secure
server, which provided immediate automated responses. This tele-
monitoring service provided reminders when BP readings were
overdue. The digital readings were available for use by the clinical team
at follow-up appointments via the woman’s App or the study website.
Women recording their home readings in a diary were asked to bring
their diary to their antenatal follow-up visits to share their readings
with their clinical team. In addition to receiving training about how to
best measure their BP and symptoms of pregnancy hypertensive dis-
ease, women were also provided with guidance about normal and out-
of-range readings using an algorithm the study team had created based
on the UK NICE Hypertension in Pregnancy guideline [8] (see
Supplementary information 1 for study materials) and how and when to
contact their local clinical team for out-of-range readings or symptoms.
This same algorithm was used to generate the immediate responses
provided through the telemonitoring system.
All women, depending on their gestation at recruitment, were asked
to attend up to three antenatal study visits at 20, 28 and 32weeks’
gestation, and one six week postnatal face-to-face or telephone study
visit. At these visits, BP measurement was taken by the study team
using the Microlife WatchBP Home monitor. Delivery outcome data
were collected from the maternity record within three months of de-
livery.
Table 2
Feasibility outcomes for 158 pregnant women with hypertension included in the OPTIMUM-BP feasibility trial from December 2015 until December 2017.
Overall recruitment 71% (158 randomised, 222 eligible*)
Chronic hypertension recruitment 65% (86 randomised, 133 eligible*)
Gestational hypertension recruitment 81% (72 randomised, 89 eligible*)
Recruitment totals per centre n (%) Total CH GH
Guy’s and St Thomas’ NHS Foundation Trust 68 (43%) 47 (55%) 21 (29%)
Oxford University Hospitals NHS Foundation Trust 51 (32%) 27 (31%) 24 (33%)
New Cross Hospital, Royal Wolverhampton NHS Trust 19 (12%) 12 (14%) 7 (10%)
King’s College Hospital NHS Foundation Trust 20 (13%) 0 (0%) 20 (28%)
Overall recruitment rate per site per month 2.5 (158 randomised, cumulative 64months recruitment period over four sites)
Chronic hypertension recruitment rate per site per month 2.8 (86 randomised, 31months recruiting)
Gestational hypertension recruitment rate per site per month 2.2 (72 randomised, 33months recruiting)
Adherence with study visits Total SMBP Usual Care
Chronic hypertension group N=83 N=53 N=30
Applicable antenatal study visits 89% (175/197) 88% (107/121) 90% (68/76)
6weeks postnatal study visit 72% (60/83) 72% (38/53) 73% (22/30)
Gestational hypertension group N=71 N=49 N=22
Applicable antenatal study visits 83% (19/23) 77% (13/17) 100% (6/6)
6weeks postnatal study visit 73% (52/71) 74% (36/49) 73% (16/22)
Discontinuation with SMBP intervention**
Chronic hypertension group 7% (4/55 originally randomised to SMBP)
Gestational hypertension group 4% (2/49 originally randomised to SMBP)
Fidelity with assigned randomisation group***
Chronic hypertension group 39% (12 started SMBP/31 randomised to usual care)
Gestational hypertension group 17% (4 started SMBP/23 randomised to usual care)
Adherence with SMBP protocolα
Chronic hypertension group N=50
Median (IQR) number of BP readings days per weekβ 5.5 (3.1 to 6.5)
Median (IQR) number of monitor readings per day on days monitoredβ 2.2 (2.1 to 2.5)
Gestational hypertension groupα N=43
Median (IQR) number of BP readings days per weekβ 6.1 (4.5 to 6.7)
Median (IQR) number of monitor readings per day on days monitoredβ 2.9 (2.5 to 4.6)
* Deducting 4 women who were found later not to be eligible (see Fig. 1).
** Participants who actively withdrew from SMBP and completed a study discontinuation form.
*** Proportion of usual care group starting SMBP with evidence of SMBP readings recorded in clinical notes.
α From women who supplied home data using BP monitor, App or BP diary data where available.
β Deducting any antenatal admission dates for a woman where she was not expected to self-monitor.
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Clinical teams at the study sites received update training on the
standardised method for measuring BP [26] and were advised to record
three readings at each antenatal follow-up visit. The average of all three
clinic readings on any single occasion was taken as the clinic BP for that
episode.
2.3. Analyses
The primary outcomes were for feasibility, measured by recruit-
ment, discontinuation, and adherence and persistence with the self-
monitoring protocol. Secondary outcomes included several measures of
BP control (to best inform the design and analysis of a future large
multi-site RCT), delivery outcomes and safety, health resource use,
quality of life scores, antihypertensive prescribing behaviour and self-
reported medication beliefs and adherence.
No formal sample size calculation was used but we aimed for a
target sample size of 160, consistent with the feasibility design [ap-
proximately half with gestational hypertension and half with chronic
hypertension] [27]. An intention to treat analysis was performed, with
the woman as the unit of analysis using all available data, with no
imputation for missing data. The statistical software Stata/SE version
14 was used for all analyses. Diﬀerences between randomisation groups
are reported with 95% conﬁdence intervals (95% CI), not including
formal signiﬁcance tests.
Analyses are reported separately by hypertension group due to the
women having slight variance in the method for BP reporting (BP diarys
for those with chronic hypertension and text/App for those with ge-
stational hypertension) and also due to the later gestations of diagnosis
and hence recruitment for those with gestational hypertension. Study
and clinic BP were analysed using a linear mixed eﬀects regression
model with unstructured covariance. The model accounted for repeated
measurements on the same participant by means of random eﬀects and
adjusted for site and study baseline BP as ﬁxed eﬀects, with interaction
between randomisation group and categorical study visit for study BP
or interaction between randomisation group and continuous quadratic
time measured in weeks of gestation for clinic BP analyses, allowing the
model to accommodate a mid-trimester BP dip. Study BP analysis for
the group with gestational hypertension used a linear regression model,
adjusted for recruiting centre and study baseline BP. A repeated mea-
sures model was not used for this group as there were insuﬃcient study
visit data due to their later gestations at enrolment into the study.
(Further statistical analysis details are supplied in Supplementary in-
formation 2).
3. Results
Between December 2015 and December 2017, 1140 women were
screened for trial eligibility (Fig. 1) of whom 226 were eligible and 162
provided written consent (target 160). Most women did not provide a
reason for declining study enrolment, but the number of women stating
they were declining due to speciﬁcally not wanting to be randomised to
either intervention group were 15% (20/134) and 7% (6/92) for those
with chronic and gestational hypertension respectively (details in
Fig. 1). Four women were recruited in error [as ineligible] and excluded
from further analysis leaving one hundred and ﬁfty-eight women; for
women with chronic hypertension: 55 were randomised to self-mon-
itoring and 31 to usual care and for women with gestational hy-
pertension: 49 were randomised to self-monitoring and 23 to usual care.
Participants not included in the analysis of clinical outcomes were three
with chronic hypertension (two for early miscarriages and one early
withdrawal by clinician on medically unrelated grounds) and one with
gestational hypertension (lost early to follow-up as emigrated).
Baseline characteristics were generally similar between the alloca-
tion groups (Table 1) for women with chronic and gestational hy-
pertension, except within the group with chronic hypertension, where
there were relative imbalances in ethnicity and previous diagnosis of a
pregnancy hypertensive disorder (see Table 1). Overall, women iden-
tifying as a non-white ethnicity accounted for 35% (55/158) and the
mean IMD score was 4.8 (SD 2.8) across groups (see Table 1 for details).
Thirty-eight percent (60/158) had performed BP home monitoring at
least once in the current pregnancy prior to enrolment, the majority of
these from the group with chronic hypertension.
3.1. Feasibility outcomes
The main feasibility outcomes are described using the combined
groups (i.e. all participants both chronic and gestational hypertension).
The proportion of those eligible that were recruited was 71% (222
eligible, 158 randomised, see Table 2). The overall randomisation rate
was 2.5 participants per site per month.
Formal discontinuation of self-monitoring of BP by women rando-
mised to the intervention group was low, with a combined rate of 6%
(6/104), three of whom still supplied some home BP monitoring data
until discontinuation. None of these women withdrew consent for notes
review follow-up. The 49 women with chronic hypertension who pro-
vided home readings reported BP measurements on a median of
5.5 days per week (IQR 3.1–6.5) and median of 2.2 readings per day
(IQR 2.1–2.5). Three women (7%) from the intervention group pro-
vided no home readings at all (two who formally discontinued with
intervention very early in follow-up and one who never supplied home
Fig. 2. Persistence with self-monitoring of blood pressure. A: Proportion of time
women with chronic hypertension persisted with self-monitoring of blood
pressure. Persistence of self-monitoring of BP (SMBP) for 50 women with
chronic hypertension providing SMBP data. Of 53 randomised to SMBP: 4
formally discontinued from the intervention, 2 of whom still supplied home
data, 2 who never started SMBP and 1 who did not formally discontinue but did
not supply data. B: Proportion of time women with gestational hypertension
persisted with self-monitoring of blood pressure. Persistence of self-monitoring
of BP for 43 women with gestational hypertension providing SMBP data. Of 49
women randomised to SMBP: 2 formally discontinued from the intervention, 1
of who still supplied data, 1 who never started SMBP and 5 who did not for-
mally discontinue but did not supply data.
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data). The 43 women with gestational hypertension provided home
readings on a median of 6.1 days per week (IQR 4.5–6.7) with a median
of 2.9 readings per day (IQR 2.5–4.6). Six women (12%) from the ge-
stational hypertension intervention group provided no home readings
(one who formally discontinued with intervention very early and ﬁve
who never supplied data). In terms of cross-over from control to some
form of self-initiated BP self-monitoring, there was evidence of this in
the maternity notes from 12/31 (39%) randomised to usual care from
the chronic hypertension group, and four from the 23 (17%) from the
gestational hypertension group.
There was high persistence with the self-monitoring intervention
(see Fig. 2) with 86% (43/50 of those supplying home data) of women
with chronic and 76% (38/49) of women with gestational hypertension
providing home BP readings for 80% or more of their time from en-
rolment until delivery.
3.2. Clinical outcomes
The mean clinic systolic and diastolic BP proﬁles throughout preg-
nancy by allocation group are presented in Fig. 3A–D. For both the
chronic and gestational hypertension groups, no diﬀerence was ob-
served between intervention groups for any measures of systolic BP
control for either study or clinic measurements (see Fig. 3A and C and
Supplement Tables 1A-B). In terms of diastolic BP, there was no dif-
ference between groups for those with gestational hypertension but for
chronic hypertension, diastolic BP was higher in the self-monitoring
group compared to usual care (mean and time-weighted mean clinic
diastolic BP) (Supplement Table 2A). A post-hoc sensitivity analysis
excluding those readings taken in the maternity assessment unit sub-
sequent to women reporting high home BP measurements, seeking to
reduce possible detection bias between groups, had no discernible im-
pact on the pattern of the original results.
No between-group diﬀerences were seen in mean deﬁned daily
dose, nor the mean number of antihypertensive medications
(Supplement Tables 1A and B). Similarly, the medication adherence and
beliefs about medication scores showed no diﬀerence between study
groups (Supplement Tables 1A and B). Maternal and perinatal outcomes
(Table 3) for women with chronic and gestational hypertension were
also similar between groups.
3.3. Adverse events, quality of life and BP monitoring preference
There was one unrelated serious adverse event reported for a
woman from the BP self-monitoring arm in the gestational hypertension
group with a case of postnatal inﬂuenza.
No between-group diﬀerences were seen at baseline, or at six weeks
postnatal in participants’ mean self-reported overall ﬁve-domain EQ-
5D-5L, visual analogue score (VAS) [20] or STAI-6 scores [21] in either
hypertension group (see Supplemental Table 3). Assessment of parti-
cipant BP monitoring preferences (from respondents to Little’s “pro-
blem score” questionnaire undertaken postnatally [28]), indicated that
clinic BP monitoring caused more anxiety than home monitoring (re-
lated to waiting around, worrying about knowing what the BP was),
whereas home monitoring scored more highly on all three positive
factors: feeling in control, good use of clinician time, worth the trouble
to get accurate readings (see Supplemental Table 4). There was a lower
overall ’problem score’ for the home BP monitoring group compared
with usual care clinic monitoring, for both chronic and gestational
hypertension groups: mean diﬀerence score (95% CI) −0.3 (−0.5 to
−0.02) and −0.7 (−0.9 to −0.4) respectively.
4. Discussion
This is the ﬁrst randomised controlled trial looking at the feasibility
of BP self-monitoring for the management of women with pregnancy
hypertension. Recruitment, follow-up, and adherence with the
Fig. 3. A-D: Clinic blood pressure across gestation for (A-B) women with chronic hypertension and (C-D) women with gestational hypertension, by randomisation
group. A. Mean clinic SBP across gestation in pregnant women with chronic hypertension. B. Mean clinic DBP across gestation in pregnant women with chronic
hypertension. C. Mean clinic SBP across gestation in pregnant women with gestational hypertension. D. Mean clinic DBP across gestation in pregnant women with
gestational hypertension. The number of participants with chronic hypertension (A &B): 10–13.9 weeks (n=8 SMBP and 5 UC) 14–17.9 weeks (n= 23 SMBP and 16
UC) 18–21.9 weeks (n= 34 SMBP and 19 UC) 22–25.9 weeks (45 SMBP and 27 UC) 26–29.9 weeks (n= 44 SMBP, 28 UC), 30–33.9 weeks (n= 42 SMBP, 25 UC),
34–37.9 weeks (n= 44 SMBP, 28 UC), 38–41.9 weeks (n= 22 SMBP, 10 UC). The number of participants with gestational hypertension (C&D): 26–29.9 weeks
(n=6 SMBP, 1 UC), 30–33.9 weeks (n= 17 SMBP, 7 UC), 34–37.9 weeks (n= 44 SMBP, 20 UC), 38–41.9 weeks (n=24 SMBP, 8 UC). SMBP: self-monitoring of
blood pressure, UC: usual care.
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intervention were much greater than average rates quoted for UK
randomised trials [29]. Persistence with the self-monitoring interven-
tion was high across both types of hypertension group and supports the
hypothesis that self-monitoring is acceptable in this population. This is
consistent with women reporting no diﬀerences in anxiety or quality of
life scores between randomised groups, and indicating a greater pre-
ference with lower “problem scores” for BP self-monitoring versus usual
clinic monitoring [28].
The study was not powered to detect a diﬀerence between rando-
misation groups for the secondary outcomes concerning BP control and
delivery outcomes hence caution must be taken in drawing conclusions.
Systolic BP in all groups and diastolic BP in gestational hypertension
did not show any diﬀerences, although we saw a small and statistically
signiﬁcant increase in mean diastolic and time-weighted mean diastolic
clinic BP for the group using self-monitoring versus usual care in
women with chronic hypertension. The greater proportion of caesarean
sections within the self-monitoring versus usual care group for women
with chronic hypertension is likely to be a chance ﬁnding but there was
a consistent trend for higher rates of pre-eclampsia, greater proportion
born prematurely less than 34weeks, reduced birth weight and greater
proportion less than tenth centile for weight for this group. It seems
unlikely that self-monitoring of BP increases adverse outcomes of this
nature, particularly as our prescribing and medication adherence data
did not reveal any diﬀerence between the randomisation groups.
Chance imbalances in outcomes between randomisation groups are
likely in feasibility trials with smaller sample sizes; we saw evidence for
this within two known important predictors of perinatal outcome
(ethnicity and previous pregnancy hypertensive disorder) within the
group with chronic hypertension. The small numbers used for feasi-
bility studies also preclude them being able to successfully minimise or
adjust for all important confounders in the randomisation and analyses
of such studies.
Table 3
Maternal and perinatal outcomes for 154 pregnant women with chronic and gestational hypertension included in the OPTIMUM-BP feasibility trial from December
2015 until December 2017.
Chronic Hypertension Gestational Hypertension
Characteristic SMBP
Group
N=53
Usual Care
Group
N=30
Adjustedα Odds Ratio or
Diﬀerence in Mean/Median
(95% CI)
SMBP
Group
N=49
Usual Care
Group
N=22
Adjustedα Odds Ratio or Diﬀerence
in Mean/Median (95% CI)
Maternal outcomes
Time between randomisation and delivery*,
days
142 (34) 150 (32) 31 (24) 25 (17)
Need for IV antihypertensive drugs week
before delivery
5 (9%) 0 (0%) 0 (0%) 0 (0%)
Onset of delivery:
Spontaneous 3 (5%) 2 (7%) 6 (12%) 7 (32%)
Induction 30 (57%) 22 (73%) 32 (66%) 7 (32%)
Pre-labour caesarean section 20 (38%) 6 (20%) 11 (22%) 8 (36%)
Indication for induction of labour/pre-labour caesarean section (all that apply):
Preeclampsia 15 (28%) 2 (7%) 15 (31%) 8 (36%)
Hypertension 12 (23%) 2 (7%) 4 (8%) 1 (5%)
Fetal growth restriction 4 (8%) 3 (10%) 4 (8%) 2 (10%)
Preeclampsia
Total 19 (36%) 5 (17%) 2.9 (0.9 to 9.1) 19 (39%) 8 (36%) 1.1 (0.4 to 3.4)
Deﬁned by new proteinuria only 5 (9%) 2 (7%) 8 (16%) 2 (9%)
Other maternal organ dysfunction 10 (19%) 2 (7%) 9 (18%) 3 (14%)
With fetal growth restriction 6 (11%) 2 (7%) 4 (8%) 4 (18%)
Adverse maternal outcome¥ 0 (0%) 1 (3%) 1 (2%) 1 (4%)
Admitted to ITU 0 (0%) 0 (0%) 1 (2%) 0 (0%)
Total admission nights‡ 5 (3 to 8) 4 (2 to 5) 4 (3 to 6) 3 (2 to 6)
Perinatal outcomes N=53 N=30 N=49 N=22
Gestation at delivery* (weeks) 36.9 (4.2) 37.9 (2.4) −1.1 (-2.8 to 0.6) 38.0 (2.0) 37.6 (2.4) 0.4 (-0.7 to 1.5)
Preterm birth (< 34weeks) 7 (13%) 2 (7%) 2.5 (0.5 to 13.7) 2 (4%) 2 (9%) 0.4 (0.1 to 3.2)
Mode of delivery, n (%)
Spontaneous vaginal delivery 13 (25%) 15 (50%) 21 (43%) 9 (41%)
Assisted vaginal delivery 1 (2%) 4 (13%) 4 (8%) 4 (18%)
Emergency pre-labour caesarean section 15 (28%) 4 (13%) 4 (8%) 5 (23%)
Emergency caesarean section in labour 10 (19%) 2 (7%) 11 (22%) 1 (4%)
Elective pre-labour caesarean section 14 (26%) 5 (17%) 9 (18%) 3 (14%)
Total with caesarean section, n (%) 39 (74%) 11 (37%) 4.9 (1.8 to 13.2) 25 (51%) 13 (59%) 1.4 (0.5 to 3.9)
Birth weight* (grams) 2808 (9 4 0) 3086 (6 2 8) −300.2 (-690.7 to 90.2) 3061 (7 3 8) 3003 (8 5 1) 54.2 (-341.7 to 450.0)
Birth weight < 10th centile† 8 (15%) 1 (3%) 5.3 (0.6 to 45.8) 9 (18%) 4 (18%) 1.3 (0.3 to 5.4)
Birth weight < 3rd centile† 2 (4%) 1 (3%) 2 (4%) 0 (0%)
Perinatal death:
Stillbirth 2 (4%) 0 (0%) 0 (0%) 0 (0%)
Neonatal death 1 (2%) 0 (0%) 0 (0%) 0 (0%)
Admitted to neonatal unit 9 (17%) 4 (13%) 1.4 (0.4 to 5.3) 9 (18%) 2 (9%) 2.2 (0.4 to 11.5)
Total admission nights‡ ** 3 (2 to 6) 2 (1 to 4) 2 (2 to 4) 3 (2 to 4)
¥ Adverse maternal outcome: eclampsia (1), intracranial haemorrhage or infarct (0), HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome (0) or
death (0).
* Mean and SD.
† Using intergrowth-21st, accessed https://www.intergrowth21.org.uk/.
‡ Median and IQR.
** Does not contain data for the two stillbirths.
α Adjusted for study site and baseline clinic SBP.
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4.1. Previous literature
Previous studies in the non-pregnant population with hypertension
have shown that self-monitoring accompanied with self-management
produces improved BP control, is preferred by participants to usual care
[11–13] and provided the impetus for this study. To our knowledge, the
only previous randomised controlled trial of self-monitoring of BP in
pregnancy included a general pregnant population rather than hy-
pertensive women [30]. Observational and qualitative studies have
reported increased satisfaction from self-monitoring but could not
evaluate clinical eﬀectiveness [31–33].
4.2. Strengths and limitations
The study beneﬁted from being run across four NHS sites and re-
cruiting from women with a range of ethnicities and socioeconomic and
educational backgrounds, supporting the concept that BP self-mon-
itoring is feasible and acceptable for a wide range of women whose
pregnancies are complicated by hypertension. The high adherence and
persistence with the self-monitoring intervention is reassuring given the
high recruitment proportion of more than 70% of those eligible. The
recruitment rate of 2.5 per site per month suggests that this is a feasible
intervention to trial on a larger scale.
The trial was run pragmatically using clinic measurements in ad-
dition to study BP readings and has shown the feasibility of collecting
and using routine clinical data. This is important in pregnancy where
attendance at study visits is problematic and aﬀected by later study
entry and premature delivery (for example< 25% of those with ge-
stational hypertension attended a study visit at 34/40 whereas all had
clinic BP data). The rapidly dynamic nature of BP change in pregnancy
is such that intermittent study visits less accurately portray underlying
BP trends. Randomisation using allocation concealment limited selec-
tion bias. Although it was not possible to mask the participants or
clinicians to randomisation group due to the nature of the intervention,
providing additional reminders to clinical teams during site visits re-
garding best practice for BP measurement helped to limit detection
bias.
While it is possible that there may be some inaccuracy of reporting
BP readings by participating women, via text, study App or recorded in
diarys, accuracy in similar studies has been shown to be high (94%
identical and only 1% submitted at a diﬀerent BP threshold) [34].
Accuracy of BP reporting is forming part of an exploratory analysis to
be published.
The study detected evidence of cross-over between groups, (17–39%
of our usual care group with gestational and chronic hypertension re-
spectively taking up some form of home monitoring); however, the
evidence from the non-pregnant hypertensive population has shown
that informal self-monitoring alone has limited impact on BP control as
opposed to self-monitoring combined with active intervention [11,12].
4.3. Clinical and research implications
In higher risk pregnancy, the motivation of pregnant women for
greater involvement in their care, the need to provide eﬀective sus-
tainable health care pathways and the opportunities from real-time
participant data collection are met in a BP self-monitoring intervention.
This is the only published randomised study to date investigating the
use of BP self-monitoring in a pregnant hypertensive population and
shows that it is feasible and acceptable. Self-monitoring could be one
way to achieve tighter BP control as shown to be beneﬁcial in the
general adult population [12] and the CHIPS study [7]. This provides
the justiﬁcation for further exploring the role of BP self-monitoring in
hypertensive pregnancies.
5. Conclusion
BP self-monitoring for the management of hypertension during
pregnancy is feasible and well tolerated by women when combined
with clinic monitoring. A large scale randomised controlled trial pow-
ered to explore the eﬀectiveness and cost-eﬀectiveness of self-mon-
itoring for improved BP control in hypertensive pregnancies is war-
ranted.
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